|

A Twenty-years' Experience in Pituitary Disease.

RECRUITINGSponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Actively Recruiting
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
Started2025-03-10
Est. completion2028-02-15
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

Pituitary tumors represent a heterogeneous group of neoplasms by histotype. The pituitary adenomas are the most frequent heteroformation, among those affecting the pituitary gland, followed by meningiomas, craniopharyngiomas, germosomes and tumours secondary, such as metastases and lymphomas. Since these conditions are considered rare, the data epidemiology and prognosis to predict the natural history of these diseases can not be considered conclusive. Pituitary adenomas are a useful model for epidemiology in the study of pathology pituitary. Over the past 20 years, several attempts have been made to identify unique prognostic factors, which predict the outcome of these pathologies, but without To arrive at a definitive classification. The purpose of this study aims to collect clinical, biochemical, morphological and pathological data on the retrospective and prospective cohort of over 1600 patients undergoing neurosurgical removal of pituitary tumors in the last 20 years, to develop a prognostic classification.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients underwent surgery for pituitary tumors;
* pathology diagnosis of pituitary tumors;
* patients older then 18 years at diagnosis of pituitary tumors;
* 2 years follow-up;

Exclusion Criteria:

* age lower then 18 years
* follow-up shorter than 2 years

Conditions4

CancerPituitary AdenomaPituitary CancerPituitary Disease

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.